Mitochondrial Permeabilization Assay for Rapid Leukemia Drug Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the therapeutic effectiveness of pharmaceutical compounds in treating leukemia and lymphoma are indirect, time-consuming, and often require analysis of surrogate markers, which is not suitable for acute forms of leukemia where rapid prediction is crucial.
Innovation Solution
An in vitro analytical process that isolates mononuclear cells from patients, incubates them with pharmaceutical compounds, and uses fluorescent dyes to measure mitochondrial outer membrane permeabilization (MOMP) in viable cells, allowing direct prediction of compound efficacy within a short time frame without the need for surrogate markers or genetic analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If indirect methods using surrogate markers or genetic analysis are used to predict therapeutic effectiveness, then measurement precision may be improved, but the analysis time is excessively long and not suitable for acute leukemia cases
Solution Approach 1:
The invention extracts and measures the direct functional effect of the pharmaceutical compound on viable tumor cells by detecting mitochondrial outer membrane permeabilization (MOMP) as a readout of apoptosis induction. This bypasses the need for indirect surrogate markers or genetic analysis, providing both high prediction accuracy and rapid results within hours rather than days or weeks.
Solution Approach 2:
The invention replaces complex genetic analysis and surrogate marker assessment with a direct functional assay measuring mitochondrial membrane permeabilization. By using fluorescent dyes to detect MOMP in viable cells, the method substitutes indirect molecular profiling with direct observation of the apoptotic mechanism itself, achieving both speed and accuracy.
2Loss of time
If fixed or permeabilized cells are used for analysis, then the analysis time is reduced, but the measurement becomes indirect and requires surrogate markers
Solution Approach 1:
The invention uses viable, unfixed, and non-permeabilized tumor cells that maintain their own physiological functions. The cells themselves provide the readout through their natural apoptotic response to the pharmaceutical compound, with MOMP serving as an intrinsic marker of apoptosis induction. This self-service approach eliminates the need for external fixation or permeabilization steps while providing direct functional measurement.
3Device complexity
If indirect methods analyzing surrogate markers are used, then device complexity may be reduced, but the ability to directly measure compound cytotoxicity in viable tumor cells is lost
Solution Approach 1:
The invention employs fluorescent dyes that change their optical properties based on mitochondrial membrane potential and permeabilization status. This color/fluorescence change provides a direct, reliable, and visually detectable readout of compound cytotoxicity in viable tumor cells, maintaining measurement reliability while keeping the methodology accessible and relatively simple.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enables rapid and direct determination of a compound's effectiveness in inducing apoptosis in leukemic cells, allowing for timely administration and monitoring of treatment response, even in acute cases, by measuring the transmembrane potential of mitochondria using FACS, thus overcoming the limitations of prior art methods.
Implementation Method 1
adding a fluorescent dye labelling active mitochondria in living cells to the separate aliquots of the medium containing the PBMC, BM or LN mononuclear cells and the pharmaceutical compound, and measuring for each of the separate aliquots on the PBMC, BM or LN mononuclear cells the transmembrane potential of mitochondria by quantification of fluorescence emitted from the dye
Data Source
Figure 1a~1b
Figure 2~3
Figure 4A~4B
AI summary
The present invention relates to an analytical in vitro process for predicting the therapeutic effectiveness of at least one pharmaceutical compound in the treatment of leukemia and/or lymphoma, the process analysing the transmembrane potential of mitochondria in cells isolated from a patient by quantification of fluorescence emitted from a dye indicating induction of apoptosis.